随机试验中抗生素最佳治疗持续时间识别方法的比较
该研究以结核病治疗为背景,通过模拟多臂多阶段连续干预反应(MAMS-ROCI)临床试验设计,比较基于模型的剂量探索方法(如MCP-Mod)与标准定性方法在确定最佳治疗持续时间和描述持续时间-反应关系方面的操作特性。结果显示,基于模型的方法在检测持续时间-反应关系、准确重现持续时间-反应曲线以及在可接受误差范围内估计最佳持续时间三个目标上均优于标准定性比较,尤其在样本量受限于典型II期试验时。
要点
- 基于模型的方法在检测持续时间-反应关系上优于标准定性比较。
- 基于模型的方法在准确重现持续时间-反应曲线方面优于标准定性方法。
- 基于模型的方法在可接受误差范围内估计最佳持续时间上优于标准定性比较。
核心结论
- 基于模型的方法在所有考察目标上均优于标准定性比较,尤其在样本量受限于典型II期试验时。
- 未来结核病治疗持续时间评估试验及更广泛的抗生素持续时间探索的成功,将 meaningful 依赖于将创新的基于模型的统计方法与重新构想的研究设计(如MAMS-ROCI)相结合的能力。
研究设计与样本
- 本研究通过模拟研究,比较适配的基于模型的持续时间探索方法与标准定性方法,模拟由多臂多阶段连续干预反应(MAMS-ROCI)临床试验设计驱动。
主要发现
- 基于模型的方法在检测持续时间-反应关系、准确重现持续时间-反应曲线以及在可接受误差范围内估计最佳持续时间三个目标上均优于标准定性比较。
- 当样本量约束为典型II期试验的样本量时,基于模型的方法优势尤为明显。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal duration of antibiotic treatment must strike a delicate balance: it must be long enough to achieve desirable efficacy yet short enough to prevent the development of toxicities, adverse events, and mitigate other arduous aspects related to patient burden. Historically, the approach used to determine duration of antibiotic treatment has been inefficient, severely impacting the refinement of therapeutics for tuberculosis (TB) where treatment duration, and its complications, can be extensive. Many of the challenges in duration-ranging have parallels and proposed solutions in the field of dose-ranging where the literature is substantially more established and where the traditions of qualitative, pairwise comparison studies have been replaced with model-based approaches. Such methods are more efficient and allow for interpolation between the doses observed. METHODS: This work examines the utility of cutting-edge dose-finding methods (such as MCP-Mod) for duration-ranging of TB treatments. We compare the operating characteristics of the adapted model-based duration-ranging methodologies against standard qualitative methods for the purposes of estimating optimal duration and describing the duration-response relationship, using a simulation study motivated by a Multi-Arm Multi-Stage Response Over Continuous Intervention (MAMS-ROCI) clinical trial design. We explore three specific targets: (1) power to detect a duration-response relationship, (2) ability to accurately reproduce the duration-response curve, and (3) ability to estimate the optimal duration within an acceptable margin of error. RESULTS: We find that model-based methods outperform standard qualitative comparisons on every target examined, particularly when the sample size is constrained to that of a typical Phase II trial. CONCLUSIONS: We conclude that the success of the next era in TB therapeutics duration evaluation trials, and antibiotics duration-ranging more broadly, will meaningfully rely on the ability to simultaneously pair innovative model-based statistical methods with re-imagined study designs such as MAMS-ROCI.
引用
- Dufault SM, Aldana BH, Phillips PPJ, et al. Comparison of methods for identifying the optimal treatment duration in randomized trials for antibiotics. Trials. 2025. PMID: 40993799. doi:10.1186/s13063-025-09050-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。